Diazoxide choline clinical trials
How each study uses diazoxide choline is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 26 Mar 2025 · VYKAT XR · NDA 216665 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2008 (2)
| Year | Studies |
|---|---|
| 2008 | 2 |
| 2011 | 1 |
| 2014 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 0
Studies
Open first, then newest update. How each study uses diazoxide choline is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- A 5 Treatment Period Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choline Controlled-Release Tablet (DCCR)WithdrawnPhase 2Essentialis, Inc.NCT02893618Written as Diazoxide choline controlled-release tablet
- Open-Label Extension Study of DCCR in Patients With Prader-Willi SyndromeCompletedPhase 3Soleno Therapeutics, Inc.NCT05701774Written as DCCR
- An Open-Label Study of Diazoxide Choline in Patients With Genetic ObesitiesWithdrawnPhase 2Soleno Therapeutics, Inc.NCT05532020Written as DCCR (diazoxide choline) extended-release tablets
- Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal PeriodCompletedPhase 3Soleno Therapeutics, Inc.NCT03714373Written as DCCR
- A Study of Diazoxide Choline in Patients With Prader-Willi SyndromeCompletedPhase 3Soleno Therapeutics, Inc.NCT03440814Written as DCCR
- An Open-Label Study of DCCR Tablet in Patients With PWSWithdrawnPhase 3Soleno Therapeutics, Inc.NCT04086810Written as DCCR
- Clinical Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi SyndromeCompletedPhase 1/2Essentialis, Inc.NCT02034071Written as DCCR
- Open-Label, Single- and Multiple-Dose Pharmacokinetic Study of Diazoxide CholineWithdrawnPhase 1Essentialis, Inc.NCT00901823Written as Diazoxide choline
- Open-label Pharmacokinetic Study of Diazoxide Choline Coated vs. Uncoated FormulationsCompletedPhase 1Essentialis, Inc.NCT00688857Written as Diazoxide choline
- Diazoxide Choline in HypertriglyceridemiaCompletedPhase 2Essentialis, Inc.NCT00696475Written as Diazoxide choline
What changed recently
From the registry's own updates since Oct 20, 2026.
Stopped1
Codes
What other systems call diazoxide choline · ClinicalTrials.gg INT002148
- MeSH (NLM) C000731842diazoxide cholineOne source NLM
- UNII (FDA) 2U8NRZ7P8LDIAZOXIDE CHOLINEConfirmed FDA, NLM, Wikidata
- Wikidata Q27255610diazoxide cholineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C213384Diazoxide CholineOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731842 | diazoxide choline | One source NLM |
| UNII (FDA) | 2U8NRZ7P8L | DIAZOXIDE CHOLINE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27255610 | diazoxide choline | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C213384 | Diazoxide Choline | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.